<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03944057</url>
  </required_header>
  <id_info>
    <org_study_id>ATG-010-MM-001</org_study_id>
    <nct_id>NCT03944057</nct_id>
  </id_info>
  <brief_title>A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma</brief_title>
  <acronym>MARCH</acronym>
  <official_title>An Open-Label, Single-Arm Study of ATG-010 Plus Dexamethasone in Patients With Multiple Myeloma Refractory to Prior Treatment With Immunomodulatory Agents and Proteasome Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antengene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antengene Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm study of ATG-010 (selinexor) plus low-dose Dexamethasone&#xD;
      (Sd) in patients with multiple myeloma previously treated with lenalidomide and bortezomib&#xD;
      refractory to prior treatment with immunomodulatory agents and proteasome Inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, open-label, multicenter study of ATG-010 (Selinexor) plus low dose&#xD;
      Dexamethasone dosed twice weekly each week in four-week cycles, in patients with&#xD;
      triple-refractory MM. The population refractory for the primary efficacy analysis will&#xD;
      contain only patients with triple-MM enrolled. PK analysis would be performed which would&#xD;
      contain approximately 30% of the patients enrolled. Safety analyses will be performed on the&#xD;
      overall population of patients who received at least one dose of study drug among&#xD;
      triple-refractory patient populations. Patients will receive treatment until progressive&#xD;
      disease (PD), death, toxicity that cannot be managed by standard care, or withdrawal,&#xD;
      whichever occurs first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the overall response rate according to IMWG 2016 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival Rate (SR)</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate survival rate at 6 months, 9 months, 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Progression (TTP)</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate duration from initiation of treatment to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical Benefit Rate (CBR=ORR+Minor Response [MR])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>12 months</time_frame>
    <description>Disease Control Rate (DCR=CBR+Stable Disease[SD])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <description>The estimates of Kaplan-Meier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD)</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the minimal residual disease in CR and sCR patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of treatment emergent adverse events (TEAEs) &amp; SAE assessed by CTCAE v4.03</measure>
    <time_frame>12 months</time_frame>
    <description>The treatment emergent adverse events (TEAEs) &amp; SAE case No. in total subject No.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the maximum plasma concentration (Cmax) of ATG-010 in Chinese patient population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration（Tmax）</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the time to reach Cmax of ATG-010 in Chinese patient population</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Relapse/Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ATG-010 + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label ATG-010 80mg plus Dexamethasone 20 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-010</intervention_name>
    <description>ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle).&#xD;
Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)</description>
    <arm_group_label>ATG-010 + Dexamethasone</arm_group_label>
    <other_name>Selinexor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent in accordance with federal, local, and institutional&#xD;
             guidelines.&#xD;
&#xD;
          2. Age ≥ 18 years at the time of signing informed consent.&#xD;
&#xD;
          3. Patients must have previously received including proteasome inhibitors (PI) (i.e.,&#xD;
             lenalidomide) and immunomodulatory drugs (i.e., bortezomib) and were refractory to&#xD;
             both drugs.&#xD;
&#xD;
          4. Any clinically significant non-hematological toxicities (except for peripheral&#xD;
             neuropathy as described in exclusion criterion #17) that patients experienced from&#xD;
             treatments in previous clinical studies must have resolved to Grade ≤ 2 by Cycle 1 Day&#xD;
             1.&#xD;
&#xD;
          5. Adequate hepatic function within 21 days prior to Cycle 1 Day 1: total bilirubin &lt; 2x&#xD;
             upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a&#xD;
             total bilirubin of &lt; 3x ULN), AST &lt; 2.5x ULN and ALT &lt; 2.5x ULN.&#xD;
&#xD;
          6. Adequate renal function within 21 days prior to Cycle 1 Day 1: estimated creatinine&#xD;
             clearance of ≥ 20 mL/min, calculated using the formula of cockroft and gault.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.&#xD;
&#xD;
          8. Measurable MM based on IMWG guidelines.&#xD;
&#xD;
          9. Adequate hematopoietic function within 21 days prior to Cycle 1 Day 1 (See Exclusion&#xD;
             Criterion #20 for transfusion washout periods for RBCs and platelets):&#xD;
&#xD;
               1. Hemoglobin level ≥ 8.5 g/dL&#xD;
&#xD;
               2. ANC ≥ 1000/mm3&#xD;
&#xD;
               3. Platelet count ≥ 75,000/mm3 (patients in whom &lt; 50% of bone marrow nucleated&#xD;
                  cells are plasma cells) or ≥ 50,000/mm3 (patients in whom ≥ 50% of bone marrow&#xD;
                  nucleated cells are plasma cells. [Platelet transfusions &lt; 1 week prior to Cycle&#xD;
                  1 Day 1 are prohibited (see below).]&#xD;
&#xD;
         10. Female subjects of child-bearing potential must have both of the following:&#xD;
&#xD;
               1. Agree to the use of two study physician-approved contraceptive methods&#xD;
                  simultaneously, or practice complete abstinence starting at the time of ICF&#xD;
                  signature, while on study medication, and 3 months following the last dose of&#xD;
                  study drug.&#xD;
&#xD;
               2. Have negative serum pregnancy test result at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of any of the following will exclude a subject from enrollment:&#xD;
&#xD;
               1. Active smoldering MM.&#xD;
&#xD;
               2. Active plasma cell leukemia.&#xD;
&#xD;
               3. Documented systemic amyloid light chain amyloidosis.&#xD;
&#xD;
               4. Active central nervous system (CNS) MM.&#xD;
&#xD;
               5. Pregnancy or breastfeeding.&#xD;
&#xD;
               6. Chemotherapy ≤ 4 week, radiation and immunotherapy ≤ 4 weeks prior to Cycle 1 Day&#xD;
                  1, and radio-immunotherapy 6 weeks prior to Cycle 1 Day 1.&#xD;
&#xD;
               7. Active graft vs. host disease (after allogeneic stem cell transplantation) at&#xD;
                  Cycle 1 Day 1&#xD;
&#xD;
               8. Life expectancy of &lt; 4 months.&#xD;
&#xD;
               9. Major surgery within four weeks prior to Cycle 1 Day 1.&#xD;
&#xD;
              10. Active, unstable cardiovascular function:&#xD;
&#xD;
                    1. Symptomatic ischemia, or&#xD;
&#xD;
                    2. Uncontrolled clinically-significant conduction abnormalities (e.g., patients&#xD;
                       with ventricular tachycardia on antiarrhythmics are excluded; patients with&#xD;
                       1st degree atrioventricular (AV) block or asymptomatic left anterior&#xD;
                       fascicular block/right bundle branch block (LAFB/RBBB) will not be&#xD;
                       excluded), or&#xD;
&#xD;
                    3. Congestive heart failure (CHF) of New York Heart Association (NYHA) Class ≥&#xD;
                       3, or&#xD;
&#xD;
                    4. Myocardial infarction (MI) within 3 months prior to Cycle 1 Day 1.&#xD;
&#xD;
              11. Prior exposure to a SINE compound, including ATG-010.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Jiao, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shimin Sun, MD</last_name>
    <phone>13701803117</phone>
    <email>jasmine.sun@antengene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhigang Lv, MD</last_name>
    <email>zhigang.lv@antengene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenming Chen, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Wenming Chen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongmei Jing, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Hongmei Jing, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial Peoples Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianyu Wen, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jianyu Wen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongqiang Wei, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yongqiang Wei, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongjun Xia, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Zhongjun Xia, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baijun Fang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Baijun Fang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central Suoth University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Liu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jing Liu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affilate Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijuan Chen, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Lijuan Chen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengzheng Fu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Zhengzheng Fu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Li, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Fei Li, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sujun Gao, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sujun Gao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuogang Liu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Zhuogang Liu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weijun Fu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Weijun Fu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital Affiliate Shanghai JiaoTong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunkang Chang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Chunkang Chang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiequn Chen, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Xiequn Chen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin blood research institute</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lugui Qiu, MD</last_name>
      <email>qiulg@ihcams.ac.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhen Cai, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Zhen Cai, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

